Tegenspraak in press release... Kan iemand mij dit verklaren??? Het aantal systemen loopt terug met 9, with a dozen systems installed in the USA??? Overigens wederom het Pharma verhaal, en er wordt niet gesproken over een teruglopend aantal systemen in Europa, sterker nog, een omzetverhoging van 207% in EMEA markets.
Iets klopt hier niet. Schacht op zijn best...
Upon completion of a pharmaceutical partner’s phase III clinical trial, Curetis in Q1-
2018 had exercised an option to buy back multiple Unyvero Systems deployed in this
clinical trial and due to financing availability has concurrently taken a cautious working
capital management approach with much stronger focus on higher priority accounts
and conversion efficiency throughout Q3-2018, which has led to a re-deployment of
Unyvero Analyzers resulting in a temporary decrease in the installed base of Unyvero
Analyzers to 166 Analyzers as of the end of the first nine months 2018, down by a
net of 9 Analyzers compared to 175 Analyzers at year-end 2017.
Since the launch, the U.S. commercial
team has qualified about 140 accounts in the top 1,000 hospitals initially targeted with
about 80 being deeply vetted. Several accounts have entered into clinical and
commercial evaluation agreements and, with a dozen Unyvero Analyzers placed
beyond FDA trial sites, have since then started the on-site evaluation of the Unyvero
System and the LRT Application Cartridge.